Hubei Biocause Pharmaceutical (000627) - Net Assets

Latest as of September 2024: CN¥36.00 Billion CNY ≈ $5.27 Billion USD

Based on the latest financial reports, Hubei Biocause Pharmaceutical (000627) has net assets worth CN¥36.00 Billion CNY (≈ $5.27 Billion USD) as of September 2024. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥285.15 Billion ≈ $41.73 Billion USD) and total liabilities (CN¥249.15 Billion ≈ $36.46 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Hubei Biocause Pharmaceutical (000627) liquid assets ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CN¥36.00 Billion
% of Total Assets	12.63%
Annual Growth Rate	19.18%
5-Year Change	-2.1%
10-Year Change	2157.69%
Growth Volatility	211.8

Hubei Biocause Pharmaceutical - Net Assets Trend (2000–2023)

This chart illustrates how Hubei Biocause Pharmaceutical's net assets have evolved over time, based on quarterly financial data. Also explore 000627 current and non-current assets for the complete picture of this company's asset base.

Annual Net Assets for Hubei Biocause Pharmaceutical (2000–2023)

The table below shows the annual net assets of Hubei Biocause Pharmaceutical from 2000 to 2023. For live valuation and market cap data, see 000627 market cap.

Year	Net Assets	Change
2023-12-31	CN¥33.63 Billion ≈ $4.92 Billion	-2.80%
2022-12-31	CN¥34.60 Billion ≈ $5.06 Billion	-7.66%
2021-12-31	CN¥37.47 Billion ≈ $5.48 Billion	+8.35%
2020-12-31	CN¥34.59 Billion ≈ $5.06 Billion	+0.68%
2019-12-31	CN¥34.35 Billion ≈ $5.03 Billion	+32.05%
2018-12-31	CN¥26.01 Billion ≈ $3.81 Billion	-2.58%
2017-12-31	CN¥26.70 Billion ≈ $3.91 Billion	+30.92%
2016-12-31	CN¥20.40 Billion ≈ $2.98 Billion	+1043.54%
2015-12-31	CN¥1.78 Billion ≈ $261.01 Million	+19.73%
2014-12-31	CN¥1.49 Billion ≈ $218.00 Million	+3.72%
2013-12-31	CN¥1.44 Billion ≈ $210.17 Million	-6.58%
2012-12-31	CN¥1.54 Billion ≈ $224.96 Million	+8.71%
2011-12-31	CN¥1.41 Billion ≈ $206.93 Million	-11.73%
2010-12-31	CN¥1.60 Billion ≈ $234.43 Million	+1.75%
2009-12-31	CN¥1.57 Billion ≈ $230.39 Million	+4.08%
2008-12-31	CN¥1.51 Billion ≈ $221.37 Million	+74.68%
2007-12-31	CN¥866.03 Million ≈ $126.73 Million	+19.67%
2006-12-31	CN¥723.71 Million ≈ $105.90 Million	-1.03%
2005-12-31	CN¥731.23 Million ≈ $107.00 Million	+1.01%
2004-12-31	CN¥723.91 Million ≈ $105.93 Million	+0.72%
2003-12-31	CN¥718.75 Million ≈ $105.18 Million	-6.41%
2002-12-31	CN¥768.02 Million ≈ $112.38 Million	+0.66%
2001-12-31	CN¥762.99 Million ≈ $111.65 Million	+28.34%
2000-12-31	CN¥594.52 Million ≈ $87.00 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Hubei Biocause Pharmaceutical's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 7134.4% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2023)

Component	Amount	Percentage
Retained Earnings	CN¥5.31 Billion	25.79%
Other Components	CN¥15.28 Billion	74.21%
Total Equity	CN¥20.59 Billion	100.00%

Hubei Biocause Pharmaceutical Competitors by Market Cap

The table below lists competitors of Hubei Biocause Pharmaceutical ranked by their market capitalization.

Company	Market Cap
MASTERBRAND INC. DL-001 F:D55	$1.13 Billion
AS LHV GROUP EO -10 F:ASU0	$1.13 Billion
CONMED Corporation NYSE:CNMD	$1.13 Billion
Atresmedia Corporación de Medios de Comunicación S.A. MC:A3M	$1.14 Billion
Hangzhou Greenda Electronic Materials Co Ltd SHG:603931	$1.13 Billion
China Reform Health Management and Services Group Co Ltd SHE:000503	$1.13 Billion
Decai Decoration Co Ltd SHG:605287	$1.13 Billion
Kumho Tire KO:073240	$1.13 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Hubei Biocause Pharmaceutical's equity between the two most recent reporting periods.

Equity Growth Insights

From 2022 to 2023, total equity changed from 21,411,955,514 to 20,590,055,885, a change of -821,899,628 (-3.8%).
Net loss of 651,758,543 reduced equity.
Dividend payments of 1,413,018,160 reduced retained earnings.
Other factors increased equity by 1,242,877,074.

Equity Change Factors (2022 to 2023)

Factor	Impact	Contribution
Net Income	CN¥-651.76 Million	-3.17%
Dividends Paid	CN¥1.41 Billion	-6.86%
Other Changes	CN¥1.24 Billion	+6.04%
Total Change	CN¥-	-3.84%

Book Value vs Market Value Analysis

This analysis compares Hubei Biocause Pharmaceutical's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 0.38x
The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2017-12-31	CN¥3.91	CN¥1.58	x
2018-12-31	CN¥3.84	CN¥1.58	x
2019-12-31	CN¥4.30	CN¥1.58	x
2020-12-31	CN¥4.28	CN¥1.58	x
2021-12-31	CN¥4.56	CN¥1.58	x
2022-12-31	CN¥4.33	CN¥1.58	x
2023-12-31	CN¥4.17	CN¥1.58	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Hubei Biocause Pharmaceutical utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -3.17%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -1.31%
• Asset Turnover: 0.16x
• Equity Multiplier: 14.66x
Recent ROE (-3.17%) is below the historical average (4.71%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2000	6.49%	10.64%	0.36x	1.68x	CN¥-18.53 Million
2001	5.41%	10.46%	0.36x	1.44x	CN¥-31.64 Million
2002	0.76%	1.51%	0.32x	1.57x	CN¥-64.13 Million
2004	0.78%	1.10%	0.43x	1.66x	CN¥-60.00 Million
2005	1.08%	1.37%	0.48x	1.65x	CN¥-58.71 Million
2006	6.84%	8.63%	0.48x	1.65x	CN¥-22.34 Million
2007	12.28%	11.97%	0.63x	1.63x	CN¥18.60 Million
2008	1.20%	1.93%	0.46x	1.35x	CN¥-128.65 Million
2009	3.31%	5.21%	0.45x	1.42x	CN¥-101.55 Million
2010	1.83%	2.25%	0.64x	1.28x	CN¥-126.18 Million
2012	0.79%	1.52%	0.38x	1.38x	CN¥-137.92 Million
2014	5.78%	7.40%	0.54x	1.46x	CN¥-61.08 Million
2015	14.21%	22.89%	0.45x	1.38x	CN¥73.30 Million
2016	12.89%	21.74%	0.07x	8.54x	CN¥398.54 Million
2017	6.86%	14.76%	0.06x	7.26x	CN¥-607.54 Million
2018	6.98%	12.01%	0.06x	9.39x	CN¥-572.69 Million
2019	8.37%	14.08%	0.06x	9.67x	CN¥-346.37 Million
2020	2.75%	4.72%	0.05x	11.33x	CN¥-1.53 Billion
2021	2.09%	3.86%	0.05x	11.70x	CN¥-1.78 Billion
2022	1.28%	0.55%	0.17x	13.48x	CN¥-1.87 Billion
2023	-3.17%	-1.31%	0.16x	14.66x	CN¥-2.71 Billion

Industry Comparison

This section compares Hubei Biocause Pharmaceutical's net assets metrics with peer companies in the Insurance - Life industry.

Industry Context

Industry: Insurance - Life
Average net assets among peers: $140,159,683,881
Average return on equity (ROE) among peers: 11.67%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Hubei Biocause Pharmaceutical (000627)	CN¥36.00 Billion	6.49%	6.92x	$1.13 Billion
COFCO Capital Holdings Co Ltd (002423)	$1.01 Billion	13.37%	0.84x	$3.45 Billion
Ping An Insurance Group Co of China Ltd (601318)	$67.16 Billion	2.11%	9.49x	$92.61 Billion
New China Life Insurance Co Ltd (601336)	$96.27 Billion	27.25%	16.58x	$19.65 Billion
China Pacific Insurance Group Co Ltd (601601)	$49.23 Billion	5.22%	5.49x	$37.29 Billion
China Life Insurance Co Ltd A (601628)	$487.13 Billion	10.42%	9.04x	$111.74 Billion

About Hubei Biocause Pharmaceutical

SHE:000627 China Insurance - Life

Market Cap

$1.13 Billion

CN¥7.75 Billion CNY

Market Cap Rank

#8572 Global

#2236 in China

Share Price

CN¥1.58

Change (1 day)

+0.00%

52-Week Range

CN¥1.39 - CN¥2.74

All Time High

CN¥10.45